A new drug jointly developed by Japanese and UK pharmaceutical companies targets HER2-positive breast cancers. It consists of a powerful chemotherapy drug linked to an antibody. In a clinical study, cancer shrank or disappeared in 60 percent of subjects. We also introduce care for patients struggling with changes in appearance due to treatment, and a cheerdance team made up of cancer survivors. The program looks at not just treatment, but ways to cope with the disease.
Metastatic breast cancer shrank significantly after 8 months of taking the drug
This doctor helped to conduct the clinical study for the new drug
Medical staff offer advice for patients struggling with changes in appearance
This cheerdance team is made up of cancer survivors